Targeted Oncology最新文献

{"title":"Correction: Regorafenib as Second-Line Versus Later-Line Therapy in Advanced Hepatocellular Carcinoma: A Multicenter Real-World Study with Exploratory Analysis of Prior Immune Checkpoint Inhibitor Exposure.","authors":"Kwon Yong Tak, Hee Sun Cho, Jaejun Lee, Kyeungmo Yang, Ahlim Lee, Ji Won Han, Soon Kyu Lee, Hyun Yang, Heechul Nam, Hee Yeon Kim, Sung Won Lee, Seok-Hwan Kim, Do Seon Song, Myeong Jun Song, Jung Hyun Kwon, UIm Chang, Soon Woo Nam, Chang Wook Kim, Jeong Won Jang, Si Hyun Bae, Hae Lim Lee, Pil Soo Sung","doi":"10.1007/s11523-026-01255-8","DOIUrl":"https://doi.org/10.1007/s11523-026-01255-8","url":null,"abstract":"","PeriodicalId":22195,"journal":{"name":"Targeted Oncology","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149115093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of PD-L1-High Tumor Expression and Association with First-Line Treatment Outcomes in Patients with Metastatic Urothelial Carcinoma: Results from a Prospective Observational Cohort Study.","authors":"Petros Grivas, Piyush K Agarwal, Hikmat Al-Ahmadie, Terence Friedlander, Daniel M Geynisman, Yair Lotan, Alicia K Morgans, Fernando J Bianco, Sreenivasa Chandana, Bruno Fang, Michael Large, Joshua J Meeks","doi":"10.1007/s11523-026-01257-6","DOIUrl":"https://doi.org/10.1007/s11523-026-01257-6","url":null,"abstract":"<p><strong>Background: </strong>Programmed death-ligand 1 (PD-L1) expression has been studied extensively in clinical trials of metastatic urothelial carcinoma.</p><p><strong>Objective: </strong>We aimed to provide information on the prevalence of tumor PD-L1 expression and treatment outcomes in patients with metastatic urothelial carcinoma in a real-world setting.</p><p><strong>Methods: </strong>PREVAIL (NCT03788746) enrolled patients with metastatic urothelial carcinoma undergoing systemic first-line treatment at US community oncology practices. The primary endpoint was the prevalence of pretreatment tumor PD-L1-high expression using an immunohistochemistry antibody for PD-L1 (SP263) [Roche Diagnostics]. Secondary endpoints included treatment patterns and association between PD-L1 expression and objective response rate (ORR), progression-free survival (PFS), and overall survival (OS).</p><p><strong>Results: </strong>Among 139 patients, the pretreatment prevalence of PD-L1-high expression was 53.2% (95% confidence interval 44.6-61.7). Forty-seven patients (33.8%) received anti-PD-L1/anti-programmed death 1 agents alone as first-line therapy. In all evaluable patients, ORR was 50.9%, median PFS was 15.1 months, and median OS was 25.4 months from the first dose of first-line therapy. There was no significant difference in PFS (hazard ratio 0.72; 95% confidence interval 0.34-1.52; p = 0.385) or OS (hazard ratio 0.71; 95% confidence interval 0.44-1.15; p = 0.164) in patients with pretreatment PD-L1-high versus PD-L1-low expression. Objective response rate was similar between patients with PD-L1-high (17/33; 51.5%) and PD-L1-low (12/24; 50.0%) expression.</p><p><strong>Conclusions: </strong>In this observational study, more than half of patients had high pretreatment tumor PD-L1 expression. There was no significant association between PD-L1 status and ORR, PFS, or OS with any first-line therapy, although definitive conclusions cannot be made because of the limited sample size.</p>","PeriodicalId":22195,"journal":{"name":"Targeted Oncology","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149115048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes by Body Mass Index in Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Treated with Inotuzumab Ozogamicin.","authors":"Wendy Stock, Ryan D Cassaday, Daniel J DeAngelo, Anjali Advani, Nicola Gokbuget, Josep Ribera, Wei Jiang, Susana Pulido, Erik Vandendries, Nathan Braniff, Elias Jabbour, Hagop Kantarjian","doi":"10.1007/s11523-026-01253-w","DOIUrl":"10.1007/s11523-026-01253-w","url":null,"abstract":"<p><strong>Background: </strong>Inotuzumab ozogamicin (lnO) is approved for the treatment of adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Elevated body mass index (BMI) could be associated with worse outcomes.</p><p><strong>Objective: </strong>To conduct post hoc BMI-stratified efficacy/safety analyses of lnO.</p><p><strong>Patients and methods: </strong>Pooled data from phase 1-4 InO trials were analyzed, with patients grouped by BMI: < 25 kg/m² (normal), 25-30 kg/m² (overweight), and > 30 kg/m² (obese), including a subset of morbidly obese (> 40 kg/m²) patients. Descriptive analyses included efficacy, safety, and pharmacokinetic simulations for InO.</p><p><strong>Results: </strong>Across 338 patients, complete remission (CR) or CR with incomplete count recovery (CRi) was achieved in 69.7%, 75.9%, 68.7%, and 84.6% patients in the < 25, 25-30, > 30, and > 40 kg/m² subgroups, respectively. The 24-month probability of progression-free survival was 19.9%, 12.8%, 10.9%, and 23.1%; the 24-month overall survival probability was 28.1%, 22.1%, 17.5%, and 23.1% in these subgroups, respectively. Most deaths were due to progressive disease. Most patients experienced treatment-emergent adverse events (TEAEs), with similar incidence across subgroups. The most common grade ≥ 3 TEAE was neutropenia (36.1%), with sinusoidal obstruction syndrome (SOS) observed in 8.3%. 143 patients (42%) proceeded to hematopoietic stem cell transplant (HSCT) after lnO treatment, with 31 (21.7%) experiencing post-HSCT SOS; the BMI > 40 kg/m² subgroup (n = 7 receiving HSCT) had the numerically highest post-HSCT non-relapse mortality. In simulations for dose capping (capped maximum dose), exposure metrics were similar across subgroups with/without dose capping.</p><p><strong>Conclusion: </strong>Efficacy/safety outcomes with InO were consistent across BMI subgroups. Dose-capping does not appear to be required.</p>","PeriodicalId":22195,"journal":{"name":"Targeted Oncology","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148983141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Osimertinib Plus Platinum-Pemetrexed: A Review in Previously Untreated, EGFR-Mutated, Locally Advanced or Metastatic NSCLC.","authors":"Amy Zhuang-Yan, Yahiya Y Syed","doi":"10.1007/s11523-026-01244-x","DOIUrl":"10.1007/s11523-026-01244-x","url":null,"abstract":"<p><p>Oral osimertinib (TAGRISSO^®) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. It is approved in several countries (including China, EU, Japan and the USA) for use in combination with platinum-pemetrexed chemotherapy as first-line treatment for adult patients with advanced non-small cell lung cancer (NSCLC) (EU) or locally advanced or metastatic NSCLC (USA) whose tumours have EGFR exon 19 deletions or exon 21 L858R mutations. In the pivotal phase III FLAURA2 trial in this patient population, osimertinib plus platinum-pemetrexed significantly prolonged median progression-free survival (PFS) and overall survival (OS) compared with osimertinib monotherapy. Osimertinib plus platinum-pemetrexed had a manageable tolerability profile, with safety consistent with that of the individual agents, and no new safety signals were identified. In conclusion, osimertinib plus platinum-pemetrexed is a valuable addition to the first-line treatment options for EGFR-mutated, locally advanced or metastatic NSCLC.</p>","PeriodicalId":22195,"journal":{"name":"Targeted Oncology","volume":" ","pages":"799-806"},"PeriodicalIF":5.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148956178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of Adverse Events Associated with MET TKIs in Patients with Advanced NSCLC: A Podcast Discussion.","authors":"Wade T Iams, Narjust Florez","doi":"10.1007/s11523-026-01242-z","DOIUrl":"10.1007/s11523-026-01242-z","url":null,"abstract":"<p><p>MET exon 14 (METex14) skipping is observed in approximately 3-4% of patients with non-small-cell lung cancer (NSCLC). These patients are typically older and may or may not have a history of tobacco use. Several small molecule MET tyrosine kinase inhibitors (TKIs) have been developed, showing clinical efficacy in trials targeting the MET pathway in these patients. Among these MET TKIs, tepotinib and capmatinib are globally approved and have demonstrated robust and durable efficacy in patients with METex14 skipping NSCLC in the VISION and GEOMETRY mono-1 trials. While MET TKIs have provided an important therapeutic option for patients with METex14 skipping NSCLC, they are associated with some challenging treatment-related adverse events (TRAEs). Across studies investigating MET TKIs, peripheral edema (49-68%) was reported as the most frequently observed TRAE and is widely recognized as a class effect of MET TKIs in patients with METex14 skipping NSCLC. Nausea (23-44%) and blood creatinine increase (22-34%) were other commonly reported TRAEs observed with treatments in this class. Effective treatment with MET TKIs relies on early recognition of AEs, regular monitoring, patient and caregiver education, and tailored supportive care interventions to ensure treatment continuity and optimal outcomes. Dose reductions have proven effective in mitigating AEs while preserving efficacy, by allowing patients to continue to receive efficacious targeted therapy. In this podcast article, the authors will discuss safety considerations with MET TKI treatment for patients with METex14 skipping NSCLC. They will also share their perspectives on the current landscape of MET TKIs in METex14 skipping NSCLC, commonly reported TRAEs in clinical practice, management strategies for these TRAEs, and safety considerations when switching one MET TKI to another. In addition, authors will discuss two patient cases to illustrate effective management of TRAEs associated with MET TKIs in patients with METex14 skipping NSCLC.</p>","PeriodicalId":22195,"journal":{"name":"Targeted Oncology","volume":" ","pages":"621-633"},"PeriodicalIF":5.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13630805/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148956645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rare Molecular Variants of Gastrointestinal Stromal Tumors (GISTs): Clinical Implications and Overview of Current Evidence.","authors":"Anna Klimczak, Katarzyna Kisielewska, Anna Szumera-Ciećkiewicz, Piotr Rutkowski","doi":"10.1007/s11523-026-01249-6","DOIUrl":"10.1007/s11523-026-01249-6","url":null,"abstract":"<p><p>Gastrointestinal stromal tumors are the most common sarcomas of the gastrointestinal tract. They are characterized by a distinct molecular profile, most frequently involving activating mutations in the KIT or PDGFRA genes, the identification of which has enabled the development of effective targeted therapies and has significantly improved patient outcomes. Despite significant therapeutic advances, treatment with tyrosine kinase inhibitors remains associated with the risk of primary or secondary resistance in a subset of patients. This phenomenon has highlighted the considerable biological heterogeneity of gastrointestinal stromal tumor, encompassing not only canonical mutational variants but also rare molecular alterations with distinct pathogenic mechanisms and clinical implications. Growing evidence suggests that detailed molecular characterization of gastrointestinal stromal tumors is of critical clinical importance, enabling improved risk stratification, optimization of treatment selection, and identification of patients requiring alternative therapeutic strategies. Therefore, comprehensive molecular diagnostics should be an integral part of the diagnostic and therapeutic approach to this heterogeneous group of tumors. The aim of this study is to provide an overview of current knowledge on rare molecular variants of gastrointestinal stromal tumors, as well as the available data on their clinical course and sensitivity to tyrosine kinase inhibitors and other therapeutic strategies.</p>","PeriodicalId":22195,"journal":{"name":"Targeted Oncology","volume":" ","pages":"701-719"},"PeriodicalIF":5.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13630833/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148725983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CDK4/6 Inhibitors in Breast Cancer Therapy: Mechanisms, Resistance, and Emerging Opportunities.","authors":"Luis Chinea, Caroline Hauer, Khushboo Pal, Hannah L Chang, Isaac S Chan","doi":"10.1007/s11523-026-01232-1","DOIUrl":"10.1007/s11523-026-01232-1","url":null,"abstract":"<p><p>Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors have significantly changed the treatment approach for hormone-receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-negative (HER2-) breast cancer in both metastatic and high-risk early-stage settings. In combination with endocrine therapy, these agents consistently improve progression-free survival, and several phase III trials have demonstrated overall survival benefit in defined populations. Their clinical activity is supported by a well-established biologic rationale targeting dysregulated cell cycle progression, a key feature of HR+ breast cancer, which drives tumor proliferation. Despite these advances, resistance remains a clinical limitation in advanced disease. Multiple mechanisms have been identified, including loss of RB1 function; amplification of CDK6, activation of cyclin E CDK2 signaling; upregulation of bypass pathways such as PI3K, AKT, mTOR, and FGFR; and acquired alterations in estrogen receptor signaling, including ESR1 mutations. Circulating tumor DNA assays are increasingly used in clinical practice and clinical trials to detect emerging genomic alterations that may allow earlier modification of therapy based on molecular progression. The post-CDK4/6-inhibitor treatment landscape has expanded substantially and now includes treatment options such as switching CDK4/6 inhibitors, targeting the PI3K-AKT pathway in patients selected for mutation, use of oral selective estrogen receptor degraders, and incorporation of antibody-drug conjugates. Ongoing studies evaluating CDK2 inhibitors, CDK4-selective agents, immunotherapy combinations, and circulating tumor DNA (ctDNA)-guided strategies aim to further refine treatment sequencing and improve long-term outcomes in HR+/HER2- breast cancer.</p>","PeriodicalId":22195,"journal":{"name":"Targeted Oncology","volume":" ","pages":"681-699"},"PeriodicalIF":5.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13630789/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148679958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of PSA Nadir on Outcomes in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Reconstructed Individual Patient Data Meta-analysis.","authors":"Mattia Alberto Di Civita, Laura Pappalardo, Danila De Angelis, Marco Stellato, Luca Zacco, Simone Rota, Eleonora Gusmaroli, Valentina Guadalupi, Iolanda Speranza, Michela Roberto, Elena Verzoni, Giuseppe Procopio, Daniele Santini","doi":"10.1007/s11523-026-01234-z","DOIUrl":"10.1007/s11523-026-01234-z","url":null,"abstract":"<p><strong>Background: </strong>Prostate cancer represents the third leading cause of cancer-related mortality in the male population. Androgen deprivation therapy efficacy has been significantly enhanced by the addition of docetaxel chemotherapy and androgen receptor pathway inhibitors (ARPI), such as abiraterone, enzalutamide, apalutamide, and darolutamide. These agents have demonstrated improvements in both overall survival (OS) and progression-free survival (PFS). Nevertheless, a subset of patients eventually progresses to metastatic castration-resistant prostate cancer (mCRPC). The prostate-specific antigen (PSA) nadir, defined as the lowest PSA level achieved during therapy, has emerged as an early surrogate marker of treatment response and favorable prognosis.</p><p><strong>Objective: </strong>We conducted a meta-analysis to elucidate the prognostic value of the depth of PSA response in patients with metastatic metastatic hormone-sensitive prostate cancer (mHSPC) treated with ARPI or docetaxel.</p><p><strong>Patients and methods: </strong>This is a reconstructed individual patient data (IPD) meta-analysis, in which prospective and retrospective clinical trials concerning patients with mHSPC who received first-line therapy with an ARPI or docetaxel were included. Prospective or retrospective studies on mHSPC patients with available data on the lowest value of PSA reached were included. IPD from the Kaplan-Meier curves of enrolled studies were obtained with the software IPDfromKM. Primary endpoints of the analysis were overall survival (OS) and progression-free survival (PFS) in patients who reached a PSA nadir ≤ 0.2 versus PSA nadir > 0.2.</p><p><strong>Results: </strong>A total of 8 reports from 8 studies were included, collecting data from 1638 patients for the OS analysis and 1104 for the PFS analysis. In terms of median PFS (mPFS), the PSA nadir ≤ 0.2 arm had an advantage: mPFS not reached (NR) versus 12.1 months HR 0.19 (95% CI 0.16-0.23, p < 0.0001). In terms of median OS (mOS) the PSA nadir ≤ 0.2 arm had an advantage compared with the PSA nadir > 0.2: mOS 92.8 months versus 34 months (HR 0.27, 95% CI 0.22-0.33, p < 0.0001).</p><p><strong>Conclusions: </strong>This meta-analysis confirms the prognostic value of PSA nadir in patients with mHSPC treated with docetaxel or ARPIs. Achieving a PSA nadir ≤ 0.2 ng/mL was significantly associated with improved OS and PFS, highlighting its relevance as an early marker of treatment efficacy.</p>","PeriodicalId":22195,"journal":{"name":"Targeted Oncology","volume":" ","pages":"657-667"},"PeriodicalIF":5.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13630845/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148689879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Regorafenib as Second-Line Versus Later-Line Therapy in Advanced Hepatocellular Carcinoma: A Multicenter Real-World Study with Exploratory Analysis of Prior Immune Checkpoint Inhibitor Exposure.","authors":"Kwon Yong Tak, Hee Sun Cho, Jaejun Lee, Kyeungmo Yang, Ahlim Lee, Ji Won Han, Soon Kyu Lee, Hyun Yang, Heechul Nam, Hee Yeon Kim, Sung Won Lee, Seok-Hwan Kim, Do Seon Song, Myeong Jun Song, Jung Hyun Kwon, UIm Chang, Soon Woo Nam, Chang Wook Kim, Jeong Won Jang, Si Hyun Bae, Hae Lim Lee, Pil Soo Sung","doi":"10.1007/s11523-026-01252-x","DOIUrl":"10.1007/s11523-026-01252-x","url":null,"abstract":"<p><strong>Background: </strong>The therapeutic paradigm for advanced hepatocellular carcinoma has shifted with the global adoption of immune checkpoint inhibitor-based regimens, leading to the frequent use of multi-tyrosine kinase inhibitors in later treatment lines.</p><p><strong>Objective: </strong>This study aimed to evaluate the real-world efficacy and safety of regorafenib as a later-line salvage therapy compared with its conventional second-line application within contemporary clinical practice.</p><p><strong>Methods: </strong>This study included 255 patients with advanced hepatocellular carcinoma treated with regorafenib between 2017 and 2026. Clinical outcomes, including objective response rate, disease control rate, overall survival (OS), progression-free survival (PFS), and time to progression, were compared between patients receiving regorafenib as a second-line versus later-line therapy.</p><p><strong>Results: </strong>Of the 255 enrolled patients, 209 received regorafenib as a second-line therapy and 46 as a later-line therapy. The mean maintained dose was significantly lower in the later-line group than in the second-line group. The overall objective response rate and disease control rate were 11.0% and 39.2%, with no significant differences between the second-line and later-line groups in the objective response rate or disease control rate. The median OS, PFS, and time to progression showed no significant difference between the second-line group and the later-line group. Within the later-line group, prior immune checkpoint inhibitor history was not significantly associated with OS or PFS. Discontinuation because of adverse events and liver dysfunction was more frequent in the later-line group than in the second-line group, whereas the rate due to cancer progression was lower. An association was observed between the development of hand-foot skin reaction (HFSR) and survival outcomes, with patients experiencing HFSR generally showing longer OS and PFS periods. Grade 3-4 HFSR was associated with the best outcomes for OS and PFS compared with the no HFSR group. On multivariate analysis, Child-Pugh class A, smaller tumor size, lower alpha-fetoprotein levels, and the absence of portal vein tumor thrombosis independently predicted longer OS.</p><p><strong>Conclusions: </strong>Regorafenib may remain a feasible salvage option in selected patients receiving later-line therapy, including those with prior immune checkpoint inhibitor exposure. Although the cumulative treatment burden leads to higher rates of toxicity-related discontinuation, observed OS and PFS did not differ significantly between treatment lines. However, the lack of significant differences in observed OS and PFS should be interpreted cautiously in the context of treatment-selection bias and small later-line subgroup size.</p>","PeriodicalId":22195,"journal":{"name":"Targeted Oncology","volume":" ","pages":"761-773"},"PeriodicalIF":5.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148875989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"P-VERIFY: Real-World Comparative Overall Survival and Progression-Free Survival of CDK4/6 Inhibitors Plus an Aromatase Inhibitor in Patients with HR+/HER2- Metastatic Breast Cancer in the USA-A Vodcast.","authors":"Hope S Rugo, Joanne C Ryan","doi":"10.1007/s11523-026-01233-0","DOIUrl":"10.1007/s11523-026-01233-0","url":null,"abstract":"<p><p>To date, there have been no head-to-head randomized controlled trial data comparing cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in patients with HR+/HER2- metastatic breast cancer (mBC), and most prior real-world comparative effectiveness studies have been limited by short follow-up times and small patient sample sizes. In this vodcast, we provide an overview of two recent publications reporting overall survival (OS) and real-world progression-free survival (rwPFS) results from P-VERIFY, a retrospective comparative effectiveness study of CDK4/6 inhibitors plus an aromatase inhibitor (AI) among patients with HR+/HER2- mBC treated in routine clinical practice in the USA. P-VERIFY used the Flatiron Health Analytic Database to identify 9146 patients who initiated first-line (1L) treatment with palbociclib (n = 6831), ribociclib (n = 1279), or abemaciclib (n = 1036), plus an AI, between February 2015 and November 2023. In primary analyses, there were no significant differences in OS and rwPFS between treatment groups after stabilized inverse probability treatment weighting, with hazard ratios ranging from 0.95 to 0.98 across pairwise group comparisons (all P > 0.05). Findings remained generally consistent across sensitivity and subgroup analyses and in a subanalysis of patients who started treatment in 2017 or later, when all three CDK4/6 inhibitors were commercially available. Taken together, results from P-VERIFY, the largest real-world study to date evaluating CDK4/6 inhibitor comparative effectiveness, suggest that there are no significant differences in OS and rwPFS between 1L palbociclib, ribociclib, and abemaciclib, plus an AI, in patients with HR+/HER2- mBC in US routine clinical practice.</p>","PeriodicalId":22195,"journal":{"name":"Targeted Oncology","volume":" ","pages":"635-641"},"PeriodicalIF":5.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13630836/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148679943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}